tbuckley/cabot-search huggingface dataset:
Myeloablative Treosulfan as Preparative Regimen for Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Experience.
Authors: Rudolf Trenschel, Markus Ditschkowski, Ahmet Elmaagacli, Nina K. Steckel, Michal Hlinka, Rudolf Peceny, Helmut Ottinger, Michael Koldehoff, Harry Biersack, Michael Flasshove, Dietrich W. Beelen
Journal: Blood (2004)
Association Between Performance Status and Quality of Life in Breast Cancer Patients: A Preliminary Study
Authors: Regina Nathania, Julang Fahman, Olivia J.D.A. Saroso, Wilson M. Raffaello, Helenia Putri, Felix Wijovi, Fernando Dharmaraja, Friecelie Natalie, Natasya Reina, Andree Kurniawan
Journal: Annals of Oncology (2019)
Autocrine and Paracrine Interactions Between Multiple Myeloma Cells and Bone Marrow Stromal Cells By Growth Arrest-Specific Gene 6 Crosstalk with Interleukin-6
Authors: Miki Furukawa, Ohkawara Hiroshi, Kazuei Ogawa, Kazuhiko Ikeda, Ueda Koki, Akiko Shichishima-Nakamura, Emi Ito, Jun-ichi Imai, Yuka Yanagisawa, Reiko Honma, Shinya Watanabe, Satoshi Waguri, Takayuki Ikezoe, Yasuchika Takeishi
Journal: Blood (2016)
An 86-Probe Gene Expression Signature Can Predict Survival in AML with Normal Karyotype Independently of FLT3 ITD and NPM1 Mutation Status - A Collaborative Study from the AMLCG and CALGB Study Groups.
Authors: Klaus H. Metzeler, Manuela Hummel, Clara D. Bloomfield, Karsten Spiekermann, Maria C. Sauerland, Achim Heinecke, Michael Radmacher, Guido Marcucci, Susan P. Whitman, Kati Maharry, Peter Paschka, Richard A. Larson, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Christian Buske
Journal: Blood (2007)
Distinct Impact of Imatinib on Growth In Prepubertal and Pubertal Children with Chronic Myeloid Leukemia
Authors: Haruko Shima, Mika Tokuyama, Akihiko Tanizawa, Chikako Tono, Kazuko Hamamoto, Hideki Muramatsu, Akihiro Watanabe, Noriko Hotta, Masaki Ito, Hidemitsu Kurosawa, Koji Kato, Masahito Tsurusawa, Keizo Horibe, Hiroyuki Shimada
Journal: Blood (2010)
The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.
Authors: Jason M. Jones, Ahmet Dogan, Steven C. Ziesmer, Grzegorz S. Nowakowski, Kay M. Ristow, Zhi-Zhang Yang, James R Cerhan, Stephen M. Ansell
Journal: Blood (2012)
Altered Plasma Cell Characteristics in Smoldering Myeloma and MGUS Patients with Preceding Immune-Related Conditions
Authors: Mary L Kwok, Neha Korde, Elisabet E. Manasanch, Aaron W. Flanders, Irina Maric, Katherine R Calvo, Adriana Zingone, Rene Costello, Daniel Cordaro, Audrey Sato, Marcia Mulquin, Diamond Zuchlinski, Mark Roschewski, Ola Landgren
Journal: Blood (2012)
Recurrent DNMT3A Mutations In Patients with Myelodysplastic Syndrome
Authors: Matthew J. Walter, Dong Shen, Jin Shao, Li Ding, Marcus Grillot, Michael McLellan, Robert Fulton, Heather Schmidt, Joelle Kalicki-Veizer, O'Laughlin Michelle, Peter Westervelt, John F. DiPersio, Elaine R Mardis, Richard Wilson, Timothy J Ley, Timothy Graubert
Journal: Blood (2010)
Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)
Authors: Craig S. Sauter, Isabelle Riviere, Yvette J Bernal, Xiuyan Wang, Terence J. Purdon, Sarah Yoo, Craig H Moskowitz, Sergio Giralt, Matthew J Matasar, Kevin J. Curran, Jae H Park, Michel Sadelain, Renier J. Brentjens
Journal: Blood (2014)
Mental health services: CQC warns of “perfect storm”
Authors: Gareth Iacobucci
Journal: BMJ (2019)

A shortage of skilled staff, coupled with rising demand, has created a “perfect storm” for patients using mental health and learning disability services, England’s healthcare regulator has warned. In its annual State of Care report for 2018-19, the Care Quality Commission said that although quality ratings across health and social care—including community mental health services—had been maintained overall, this masked “a real deterioration” in some specialist inpatient services over the past 12 months.1 As at 30 September 2019 the CQC reported that:
A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Authors: Fong Chun Chan, Anja Mottok, Alina S Gerrie, Maryse M Power, Kerry J Savage, Marcel Nijland, Arjan Diepstra, Anke Van den Berg, Joseph M. Connors, Randy D. Gascoyne, Sohrab P. Shah, David W. Scott, Christian Steidl
Journal: Blood (2016)
Functional and Molecular Consequences of the Dnmt3aR882H Mutation in Acute Myeloid Leukaemia
Authors: Malgorzata Gozdecka, Milena M. Mazan, Vivek Iyer, Anna Farne, Eshwar Meduri, Ruben Bautista, Nicolas Walker, Anne C Ferguson-Smith, George S. Vassiliou, Brian J.P Huntly
Journal: Blood (2015)
The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.
Authors: Melissa G Ooi, Robert O'Connor, Jana Jakubikova, Justine Meiller, Steffen Klippel, Jake Delmore, Efstathios Kastritis, Douglas McMillin, Martin Clynes, Paul Richardson, Constantine S. Mitsiades, Peter O'Gorman, Kenneth C. Anderson
Journal: Blood (2009)
No Recurrent Mutation of SF3B1, U2AF1 and SRSF2 Spliceosomal Gene in Multiple Myeloma but Polymorphisms of These Genes Are Associated with the Prediction of Worse Prognosis
Authors: Trang Nguyen Thi Dai, Hye-Ran Kim, Min-Gu Kang, Stephanie J. Won, Hwan-Young Kim, Jung-Yun Ko, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Myung-Geun Shin
Journal: Blood (2012)
Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation
Authors: Natasha A Jain, Prathima Anandi, Upneet Chawla, Sawa Ito, Debbie Draper, Eleftheria Koklanaris, Sara Hauffe, Jeanine Superata, Robert Q. Le, David Stroncek, Pawel Muranski, Minoo Battiwalla, John Barrett
Journal: Blood (2016)
The Mir-17~92 Cluster Family Determines the Responsiveness of CLL Cells with Unmutated IGHV Genes to Toll-Like Receptor 9 Triggering
Authors: Riccardo Bomben, Stefano Volinia, Stefania Gobessi, Daniela Marconi, Michele Dal Bo, Dania Benedetti, Giovanni Del Poeta, Luca Laurenti, Dimitar G Efremov, Valter Gattei
Journal: Blood (2010)
3-D Pharmacophore Identification of Second Generation Small Molecule Inhibitors of Stat3 SH2-Phosphotyrosine Binding That Induce Apoptosis in Acute Myeloid Leukemia Cells.
Authors: Redell S. Redell, Xuejun Xu, Moses M. Kasembeli, Marcos J. Ruiz, David John Tweardy
Journal: Blood (2009)
Boosting staff wellbeing improves NHS trusts’ CQC ratings, report finds
Authors: Abi Rimmer
Journal: BMJ (2019)

Initiatives to increase staff engagement and make leadership teams more approachable have helped to improve NHS trusts’ ratings from the health and social care watchdog, a report by NHS Providers has found.1

Trusts’ performance has gradually improved, showed the results of inspections by the Care Quality Commission (CQC). In 2014—the year that the CQC began rating trusts—24 of 35 trusts inspected (68%) were designated “requires improvement” or “inadequate.” Five years later, most of the 224 trusts inspected (59%) were rated “good” or “outstanding.”

In its report NHS Providers set out 11 case studies of trusts that …
A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis
Authors: Frank Stegelmann, Markus Bangerter, Florian H Heidel, Martin Griesshammer, Holger Hebart, Andreas Hochhaus, Steffen Koschmieder, Robert Möhle, Andreas Reiter, Christof Scheid, Rebecca Kirschbaum, Regina Reim, Ulrike Sutter, Katrin Vetter, Hartmut Döhner, Richard F. Schlenk, Konstanze Döhner
Journal: Blood (2015)
LFA-3/CD2 Pathway, Potential Target For Immunosuppressive Therapy In Aplastic Anemia: A Phase I/II Trial Of Alefacept In Patients With Relapsed/Refractory Aplastic Anemia
Authors: Ramon V. Tiu, Valeria Visconte, Paul Elson, Michael J. Clemente, Ali Tabarroki, Edy Hasrouni, Amy Porter, Lindsey Mooney, Manuel G. Afable, Ricki Englehaupt, Joy Juersivich, Kathleen Cooper, Mikkael A. Sekeres, Yogen Saunthararajah, Jaroslaw P. Maciejewski
Journal: Blood (2013)
Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia
Authors: Ce Shi, Lina Han, Qi Zhang, Kathryn G. Roberts, Eugene Park, Yoko Tabe, Rodrigo Omar Jacamo, Hong Mu, Shuo-Chieh Wu, Jin Zhou, Helen Ma, Zhihong Zeng, Nitin Jain, Elias J Jabbour, Markus Muschen, Sarah K Tasian, Charles G. Mullighan, David M. Weinstock, David Fruman, Marina Konopleva
Journal: Blood (2015)
Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion
Authors: Paulina Richter-Pechanska, Joachim B. Kunz, Tobias Rausch, Caroline Von Knebel Doeberitz, Viktoras Frismantas, Maria Pamela Dobay, Beat Bornhauser, Martin Zimmermann, Obul Reddy Bandapalli, Stephan Fuhrmann, Elena Orlova, Sebastian Uhrig, Gnana Prakash Balasubramanian, Martin Stanulla, Martin Schrappe, Gunnar Cario, Gabriele Escherich, Kseniya Bakharevich, Renate Kirschner-Schwabe, Cornelia Eckert, Stefan Pfister, Jan O. Korbel, Martina Muckenthaler, Jean-Pierre Bourquin, Andreas E. Kulozik
Journal: Blood (2017)
Allogeneic Suicide Gene-Modified T Cells (aSGMTC) Are Highly Cytotoxic to Non-Hematopoietic Tumor Cell Lines: Rationale for the Production of a Bank of aSGMTC for the Treatment of Solid Tumors.
Authors: Laurent Mailly, Celine Leboeuf, Christophe Ferrand, Pierre Tiberghien, Gaetan Bour, Marc Aprahamian, Michel Doffoel, Philippe Wolf, Thomas Baumert, Eric Robinet
Journal: Blood (2009)
A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies
Authors: Xiaoshu Jing, Kang Jin
Journal: Medicinal Research Reviews (2019)

Abstract As a versatile therapeutic modality, peptides attract much attention because of their great binding affinity, low toxicity, and the capability of targeting traditionally “undruggable” protein surfaces. However, the deficiency of cell permeability and metabolic stability always limits the success of in vitro bioactive peptides as drug candidates. Peptide macrocyclization is one of the most established strategies to overcome these limitations. Over the past decades, more than 40 cyclic peptide drugs have been clinically approved, the vast majority of which are derived from natural products. The de novo discovered cyclic peptides on the basis of rational design and in vitro evolution, have also enabled the binding with targets for which nature provides no solutions. The current review summarizes different classes of cyclic peptides with diverse biological activities, and presents an overview of various approaches to develop cyclic peptide‐based drug candidates, drawing upon series of examples to illustrate each strategy.
Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L
Authors: James C.H. Yang, Hye R. Kim, Myung-Ju Ahn, Ji-Youn Han, Maximilian J. Hochmair, Ki H. Lee, Angelo Delmonte, Maria R. Garcia Campelo, Dong-Wan Kim, Enriqueta Felip, Raffaele Califano, Alexander Spira, Scott Gettinger, Marcello Tiseo, Jeff Haney, David Kerstein, Sanjay Popat, D.R. Camidge
Journal: Annals of Oncology (2019)
Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells
Authors: Silvia Buonamici, Rachel Darman, Samantha Perino, Anant Agrawal, Shouyong Peng, Michael Seiler, Kian Huat Lim, Erica B. Bhavsar, Jacob Feala, Esther A. Obeng, Suzanna Bailey, Betty Chan, Peter Fekkes, Gregg F. Keaney, Pavan Kumar, Kaiko Kunii, Linda Lee, Crystal Mackenzie, Mark Matijevic, Yoshiharu Mizui, Khin Myint, Eunice Park, Ermira Pazolli, Michael Thomas, John Wang, Markus Warmuth, Lihua Yu, Ping Zhu, Richard R. Furman, Benjamin L Ebert, Peter G Smith
Journal: Blood (2015)
A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)
Authors: Chul Won Jung, Lee-Yung Shih, Zhijian Xiao, Jie Jin, Hsin-An Hou, Xin Du, Ming-Chung Wang, Seonyang Park, Ki-Seong Eom, Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Jin Seok Kim, Daobin Zhou, Andres Sirulnik, Wanda Ruiz, Taro Amagasaki, Kazuo Ito, Koichi Akashi
Journal: Blood (2013)
Significance of Initial Lumbar Puncture on Day8 of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia: The Results from the Tokyo Children’s Cancer Study Group L99-15 Protocol.
Authors: Daisuke Hasegawa, Atsushi Manabe, Akira Ohara, Katsuyoshi Koh, Chitose Ogawa, Ryoji Hanada, Masahiro Tsuchida
Journal: Blood (2008)
Down-staging and histological effects might be predictive factors for DOC+CDDP+5-FU for esophageal cancer
Authors: Kazuma Kobayashi, Kengo Kanetaka, Akira Yoneda, Shinichiro Kobayashi, Shun Yamaguchi, Hanako Tetsuo, Satomi Okada, Takahiro Enjoji, Sayaka Kuba, Chika Sakimura, Taiichiro Kosaka, Yuusuke Inoue, Shinichiro Ono, Koji Natsuda, Tomohiko Adachi, Masaaki Hidaka, Yasuhiro Torashima, Shinichiro Ito, Kosho Yamanouchi, Mitsuhisa Takatsuki, Susumu Eguchi
Journal: Annals of Oncology (2019)
Significantly Reduced Circulating Plasmacytoid Dendritic Cells In Patients with Primary and Helicobacter Pylori-Associated Immune Thrombocytopenia
Authors: Akio Saito, Akihiko Yokohama, Yohei Osaki, Yoshiyuki Ogawa, Takeki Mitsui, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Morio Sawamura, Masamitsu Karasawa, Hirokazu Murakami, Yoshihisa Nojima, Norifumi Tsukamoto
Journal: Blood (2010)
EPO-Dependent Recovery of Late-Stage Erythroid Progenitors in the Marrow Precedes Splenic Expansion: Insights From a Sublethal Radiation Model
Authors: Scott A Peslak, Jesse Wenger, Amali P Epa, Jeffrey C Bemis, Paul D Kingsley, Anne D Koniski, Kathleen E McGrath, James Palis
Journal: Blood (2011)
Inherited and Acquired Modifiers of Iron Status May Dramatically Affect the Phenotypic Expression of Dehydrated Hereditary Stomatocytosis
Authors: Corentin Orvain, Lydie Da Costa, Richard van Wijk, Serge Pissard, Veronique Picard, Lamisse Mansour-Hendili, Muriel Giansily-Blaizot, Guillaume Cartron, Jean-Francois Schved, Patricia Aguilar-Martinez
Journal: Blood (2016)
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib.
Authors: Giovanni Martinelli, Daniela Cilloni, Emanuela Ottaviani, Michele Malagola, Francesca Messa, Michela Rondoni, Costanza Bosi, Enrico Gottardi, Gianantonio Rosti, Paolo Ricci, Stavroula Gaitani, Fabrizio Pane, Nicoletta Testoni, Cristina Mecucci, Simona Soverini, Pier Paolo Piccaluga, Marilina Amabile, Mario Tiribelli, Alfonso Zaccaria, Tiziana Grafone, Antonello De Vivo, Stefano Pileri, Pierpaolo Fattori, Monica Bocchia, Anna Serra, Luca Maurillo, Renato Fanin, Nicholas C.P. Cross, Serena Merante, Mario Cazzola, Giuliana Alimena, Francesco Frassoni, Piero Galieni, Domenico Russo, Marco Gobbi, Luigi Gugliotta, Francesco Lauria, Patrizio Mazza, Felicetto Ferrara, Filippo Gherlinzoni, Pietro Leoni, Pellegrino Musto, Michele Baccarani, Giuseppe Saglio
Journal: Blood (2004)
The outcomes of imatinib therapy of advanced gastrointestinal stromal tumors (GISTs) originating from the small bowel
Authors: P. Rutkowski, Z. I. Nowecki, M. Debiec-Rychter, U. Grzesiakowska, W. Michej, A. Wozniak, J. Limon, C. Osuch, T. Switaj, W. Ruka
Journal: Journal of Clinical Oncology (2007)

10052 Background: The aim of the study was to assess the outcomes of imatinib (IM) therapy in subgroup of patients with advanced CD117(+) GIST originating from small intestine. Methods: In the group of 245 consecutive patients with inoperable and/or metastatic GIST CD117(+) treated with imatinib in the dose of 400–800mg daily and enrolled into prospectively collected Clinical GIST Registry between 09/2001 and 10/2006 we identified 123 patients (50.2%) with GIST originating from small bowel. There were 43 primary unresectable/metastatic tumors and 80 recurrent (after primary surgery) tumors. Median follow-up time was 31 months (range: 3–63). Results: The estimated 3-year progression-free survival (PFS; calculated form the date of the start of IM) and overall survival (OS) were 61% and 80%, respectively. The best responses observed during IM therapy according to RECIST criteria were as follows: complete responses (CRs) - 9 cases (7%), partial responses (PRs) - 66 cases (54%), stable disease SD - 29 cases (24%) and progressive disease (PD) - 19 (15%). In 42 analyzed specimens 29 GISTs (69%) had exon 11 KIT mutations, 9 (21%) - exon 9 KIT mutations and 4 (10%) other genetic abnormalities. We identified three factors negatively affecting PFS statistically significant (p&lt;0.05) in multivariate analysis: baseline poor WHO performance status = 2, tumor genotype with other than exon 11 KIT mutant and primary tumor mitotic index &gt;10/50HPF. Two more additional factors had negative impact on PFS in univariate analysis only: baseline high neutrophil count (p=0.04) and low baseline hemoglobin level (p=0.01). Conclusions: In analysis of the subset of patients with advanced GIST originating from the small bowel we confirmed long-term benefit from IM therapy. We identified three independent biological factors influencing the progression-free survival during imatinib therapy in this group of patients. [Table: see text]
Notch-Mediated Suppression of PKCθ Reduces Reactive Oxygen Species and Promotes Leukemic Stem Cell Activity In T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Authors: Vincenzo Giambra, Oksana Nemirovsky, Sonya Lam, Christopher Jenkins, Carol Wai, Hind Medyouf, R. Keith Humphries, Connie J. Eaves, Andrew P Weng
Journal: Blood (2010)
In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2.
Authors: Amy D. Hartman, Annique Wilson-Weekes, Larry D. Cripe, Brydon Bennett, Glenn Friedman, Peter Worland, Brian Druker, Shuyue Ren, Tomasz Skorski, H. Scott Boswell
Journal: Blood (2006)
Proteomics Analysis of Cellular Network in Human Bone Marrow Reveals Lineage Skewing Towards Megakaryocytes and Decrease in Lymphoid Development upon Aging
Authors: Anthony D. Ho, Patrick Horn, Marco Hennrich, Samira Jaeger, Natalie Romanov, Ximing Ding, Peer Bork, Patrick Aloy, Anne-Claude Gavin
Journal: Blood (2016)
Transferred Donor-Derived Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor Can Persist and Provide Anti-Leukemic Activity in AML Patients Post-Transplant
Authors: Merav Bar, Aude G. Chapuis, Thomas M Schmitt, Hieu Nguyen, Natalie A Duerkopp, Mark F Tom, Felecia D Wagener, Colette N Chaney, Kieu-Thu Bui, Shelly Heimfeld, Philip D. Greenberg
Journal: Blood (2014)
Plasma Concentration of ST2, the IL33 Receptor, At Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment
Authors: Mark T. Vander Lugt, Thomas Braun, James L.M. Ferrara, Samir Hanash, John E. Levine, Chee-Hong Wang, Qing Zhang, Alice Chin, Andrew C. Harris, Sung W.J. Choi, Daniel Couriel, Pavan Reddy, Sophie Paczesny
Journal: Blood (2011)
Targeting ß-Catenin Signaling in DLBCL with ICG-001 and PAM-1 Suppresses Cell Proliferation and Induces Apoptosis
Authors: Angela A. Fachel, Ashlesha Shrikant Muley, Cem Meydan, Xabier Agirre, Leandro Cerchietti, Ari Melnick, Kristy L. Richards
Journal: Blood (2016)
TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.
Authors: Rao Prabhala, Dheeraj Pelluru, Paola Neri, Mariateresa Fulciniti, James J. Driscoll, Song Weihua, Simona Blotta, Yu-Tzu Tai, Hiren Patel, Yvonne A. Efebera, Teru Hideshima, Dhaminder Chauhan, John F. Daley, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2007)
Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project
Authors: Jinghui Zhang, Charles Mullighan, Richard Harvey, William L. Carroll, I-Ming L. Chen, Meenakshi Devidas, Eric Larsen, Michael Edmonson, Ken Buetow, Daniela S Gerhard, Mignon L. Loh, Gregory H. Reaman, Mary V. Relling, Malcolm A Smith, James R. Downing, Cheryl L. Willman, Stephen Hunger
Journal: Blood (2010)
Cripto Selectively Expands a Distinct Population of Hematopoietic Stem Cells Expressing the Cell Surface Receptor GRP78 and Strongly Induces An Immature Phenotype In Vivo After Ex Vivo Culture
Authors: Kenichi Miharada, Göran Karlsson, Jonas Larsson, Emma Larsson, Kavitha Siva, Stefan Karlsson
Journal: Blood (2010)
Pten Inactivating Mutations Promote Loss of MYC “Oncogene Addiction” in a Conditional Zebrafish Model of T-ALL.
Authors: Alejandro Gutierrez, Hui Feng, Adele Faucherre, Jeroen Den Hertog, Edward V. Prochownik, Joseph R. Testa, John Kanki, A. Thomas Look
Journal: Blood (2009)
Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) as Frontline Therapy for CLL: Results of a Phase 2 Study.
Authors: Stefan Faderl, William G. Wierda, Susan O’Brien, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Michelle Detry, Hagop M. Kantarjian, Brandi O’Neal, Michael J. Keating
Journal: Blood (2006)
Anatomical Predictors of Venous Thromboembolism Recurrence after Isolated Superficial Vein Thrombosis
Authors: Jean-Philippe Galanaud, Marie-Antoinette Sevestre, Céline Genty, Susan R Kahn, Gilles Pernod, Dominique Brisot, Isabelle Quéré, Jean-Luc Bosson
Journal: Blood (2015)
Gram-scale synthesis of highly biocompatible and intravenous injectable hafnium oxide nanocrystal with enhanced radiotherapy efficacy for cancer theranostic
Authors: Yangyang Li, Yuchen Qi, Hongbo Zhang, Zhiming Xia, Tingting Xie, Wanlin Li, Danni Zhong, Huanle Zhu, Min Zhou
Journal: Biomaterials (2019)
Early Response to Methotrexate, Vincristine and Procarbazine Chemotherapy-Adapted Strategy for Primary CNS Lymphoma: Omitted Radiotherapy for Patients Achieving Complete Response in Interim Analysis.
Authors: Yu Ri Kim, Se Hoon Kim, Jong Hee Chang, Chang-Ok Suh, Soo Jeong Kim, yun Deok Kim, Doh Yu Hwang, Ji Eun Jang, Shin Young Hyun, June-Won Cheong, Yoo-Hong Min, Jin Seok Kim
Journal: Blood (2012)
A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12
Authors: Michael Crump, John Kuruvilla, C. Tom Kouroukis, Ann Benger, Matthew C. Cheung, Neil L Berinstein, Stephen Couban, Matthew D. Seftel, Kang Howson-Jan, Armand Keating, Massimo Federico, David A Macdonald, Harold J. Olney, Morel Rubinger, Michael Voralia, A. Robert Turner, Tara Baetz, Annette E Hay, Marina Djurfeldt, Ralph M. Meyer, Bingshu Chen, Lois Shepherd
Journal: Blood (2013)
Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638)
Authors: Umberto Vitolo, Marco Ladetto, Enrica Gamba, Luca Baldini, Manuela Ceccarelli, Annalisa Chiappella, Amalia De Renzo, Francesco Di Raimondo, Andrea Gallamini, Attilio Guarini, Barbara Mantoan, Maurizio Martelli, Isabel Alvarez, Lorella Orsucci, Guido Parvis, Mario Petrini, Antonello Pinto, Enrico Maria Pogliani, Samantha Pozzi, Alessandro Pulsoni, Luigi Rigacci, Alessandra Tucci, Francesco Zaja, Eugenio Gallo
Journal: Blood (2007)
ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance
Authors: Naseema Gangat, Terra L. Lasho, Mrinal M Patnaik, Christy Finke, Mark R Litzow, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2015)